Showing 21-30 of 31 results for "".
- OMNY Health Launches Integrated Dermatology Data Repository and Research Networkhttps://practicaldermatology.com/news/omny-health-launches-integrated-dermatology-data-repository-and-research-network/2460845/OMNY Health has partnered with community-based dermatology practices to create a first-of-a-kind integrated, normalized, de-identified electronic health record (EHR) data repository for dermatological research. The assembled longitudinal data represents care delivered over the past five years by …
- Survey: Parents Extremely Worried About the Physical and Emotional Toll that Severe Acne Takes on Teenshttps://practicaldermatology.com/news/survey-parents-extremely-worried-about-the-physical-and-emotional-toll-that-severe-acne-takes-on-teens/2460734/Parents are very worried about the effects of severe acne on their teens, according to a new survey sponsored by Sun Pharma, in collaboration with the American Acne and Rosacea Society (AARS). The survey, which polled 250 parents of teenagers with severe nodular or cystic acne, showed that the vas…
- Dermatologists React to Reports of Adverse Events in Filler Patients Who Got COVID-19 Vaccineshttps://practicaldermatology.com/news/report-covid-19-vaccines-and-dermatology/2460648/As case reports of facial swelling in patients with a history of dermal filler treatment who received Moderna’s COVID-19 vaccine accrue, dermatologists are devising new protocols for how to best address this potential phenomenon, including the optimal timing of fillers and vaccines, updated consent…
- Arcutis: Enrollment Complete for Phase 2 Study of Roflumilasthttps://practicaldermatology.com/news/arcutis-enrollment-complete-for-phase-2-study-of-roflumilast/2460446/Enrollment is now complete for the Phase 2 proof of concept clinical trial evaluating roflumilast foam for the treatment of seborrheic dermatitis. Arcutis Biotherapeutics is developing roflumilast, a selective phosphodiesterase type 4 inhibitor (PDE4 inhibitor), in a once-daily topical foam formula…
- Consumer Reports IDs Teaching Hospitals That Expose Patients to Central Line Infectionshttps://practicaldermatology.com/news/consumer-reports-ids-teaching-hospitals-that-expose-patients-to-central-line-infections/2458366/Too many teaching hospitals are still exposing patients to dangerous bacteria via central line infections, according to Consumer Reports. The new report identifies 31 U.S. teaching hospitals on its lowest-performing “zero tolerance” list and 32 on its list of top performers. About 650,000 people …
- Cloudy with a Chance of Wrinkles: ROC Ranks US Cities By Wrinkle Indexhttps://practicaldermatology.com/news/cloudy-with-a-chance-of-wrinkles-roc-ranks-cities-by-wrinkle-index/2458453/Philadelphia will be the most wrinkle-prone city in America come 2040 thanks to high stress levels, more airborne pollution, lengthy commute times and higher than average smoking rates, according to the 2016 RoC® Wrinkle Ranking. San Jose, Calif. will hold the least wrinkle-prone title in 2040 due…
- Syneron Candela Launches "Changing Lives" Program At AADhttps://practicaldermatology.com/news/syneron-candela-launches-changing-lives-program-at-aad/2458985/Syneron Medical Ltd. is introducing the Changing Lives Program, a corporate wide initiative that the company says leverages its life-changing technologies with life-changing causes. Launching at the annual American Academy of Dermatology (AAD) meeting in San Francisco on March 21, Changing Lives em…
- FDA Approves Mirvaso for Treating Facial Erythema of Rosaceahttps://practicaldermatology.com/news/20130826-fda_approves_mirvaso_for_treating_facial_erythema_of_rosacea/2459476/The FDA recently approved Mirvaso (brimonidine) gel, 0.33% for the topical treatment of the facial erythema of rosacea in adults 18 years of age or older. According to manufacturer Galderma Laboratories, applied once daily, Mirvaso works quickly to reduce the redness of rosacea and lasts up to 12 h…
- AMA Foundation Awards Research Grants To Study Issues Affecting Women In Medicinehttps://practicaldermatology.com/news/20130521-ama_foundation_awards_research_grants_to_study_issues_affecting_women_in_medicine/2459535/In 1850, the first medical institution in the world established to train women in medicine and offer opportunities of an MD opened their doors in Philadelphia. For those women, it was a chance to enter the medical world that routinely shut them out. While women today don't face such a task, importa…
- Free Skin Cancer Screenings January 26 in Southeasthttps://practicaldermatology.com/news/20130115-free_skin_cancer_screenings_january_26_in_southeast/2459636/Gulf Coast Dermatology will offer free full-body skin cancer screenings on Saturday, January 26 from 9 a.m. to noon at several of their locations. The screenings are provided by appointment only and are for new patients. Appointments for the screenings may be scheduled by calling 1-877-231-DERM (33…